Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy.

Huang C, Clayton EA, Matyunina LV, McDonald LD, Benigno BB, Vannberg F, McDonald JF.

Sci Rep. 2018 Nov 6;8(1):16444. doi: 10.1038/s41598-018-34753-5.

2.

Evidence for the importance of post-transcriptional regulatory changes in ovarian cancer progression and the contribution of miRNAs.

Zhang M, Matyunina LV, Walker LD, Chen W, Xiao H, Benigno BB, Wu R, McDonald JF.

Sci Rep. 2017 Aug 15;7(1):8171. doi: 10.1038/s41598-017-08502-z.

3.

Highly-accurate metabolomic detection of early-stage ovarian cancer.

Gaul DA, Mezencev R, Long TQ, Jones CM, Benigno BB, Gray A, Fernández FM, McDonald JF.

Sci Rep. 2015 Nov 17;5:16351. doi: 10.1038/srep16351.

4.

Glycomic analysis of membrane glycoproteins with bisecting glycosylation from ovarian cancer tissues reveals novel structures and functions.

Allam H, Aoki K, Benigno BB, McDonald JF, Mackintosh SG, Tiemeyer M, Abbott KL.

J Proteome Res. 2015 Jan 2;14(1):434-46. doi: 10.1021/pr501174p. Epub 2014 Dec 9.

5.

Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells.

Wang L, Mezencev R, Švajdler M, Benigno BB, McDonald JF.

Gynecol Oncol. 2014 Jul;134(1):96-103. doi: 10.1016/j.ygyno.2014.04.055. Epub 2014 May 4.

PMID:
24802724
6.

Transcriptional override: a regulatory network model of indirect responses to modulations in microRNA expression.

Hill CG, Matyunina LV, Walker D, Benigno BB, McDonald JF.

BMC Syst Biol. 2014 Mar 25;8:36. doi: 10.1186/1752-0509-8-36.

7.

p66Shc longevity protein regulates the proliferation of human ovarian cancer cells.

Muniyan S, Chou YW, Tsai TJ, Thomes P, Veeramani S, Benigno BB, Walker LD, McDonald JF, Khan SA, Lin FF, Lele SM, Lin MF.

Mol Carcinog. 2015 Aug;54(8):618-31. doi: 10.1002/mc.22129. Epub 2014 Jan 7.

8.

High-dose chemotherapy with autologous stem cell support as salvage therapy in recurrent gestational trophoblastic disease.

Benigno BB.

Int J Gynecol Cancer. 2013 Sep;23(7):1331-3. doi: 10.1097/IGC.0b013e3182a017fc.

PMID:
23970157
9.

Molecular profiling supports the role of epithelial-to-mesenchymal transition (EMT) in ovarian cancer metastasis.

Lili LN, Matyunina LV, Walker LD, Wells SL, Benigno BB, McDonald JF.

J Ovarian Res. 2013 Jul 10;6(1):49. doi: 10.1186/1757-2215-6-49.

10.

Molecular profiling predicts the existence of two functionally distinct classes of ovarian cancer stroma.

Lili LN, Matyunina LV, Walker LD, Benigno BB, McDonald JF.

Biomed Res Int. 2013;2013:846387. doi: 10.1155/2013/846387. Epub 2013 May 9.

11.

Evidence for the complexity of microRNA-mediated regulation in ovarian cancer: a systems approach.

Shahab SW, Matyunina LV, Mezencev R, Walker LD, Bowen NJ, Benigno BB, McDonald JF.

PLoS One. 2011;6(7):e22508. doi: 10.1371/journal.pone.0022508. Epub 2011 Jul 21.

12.

Rapid mass spectrometric metabolic profiling of blood sera detects ovarian cancer with high accuracy.

Zhou M, Guan W, Walker LD, Mezencev R, Benigno BB, Gray A, Fernández FM, McDonald JF.

Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2262-71. doi: 10.1158/1055-9965.EPI-10-0126. Epub 2010 Aug 10.

13.

Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells.

Bowen NJ, Walker LD, Matyunina LV, Logani S, Totten KA, Benigno BB, McDonald JF.

BMC Med Genomics. 2009 Dec 29;2:71. doi: 10.1186/1755-8794-2-71.

14.

Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles.

Scarberry KE, Dickerson EB, Zhang ZJ, Benigno BB, McDonald JF.

Nanomedicine. 2010 Jun;6(3):399-408. doi: 10.1016/j.nano.2009.11.003. Epub 2009 Dec 5.

PMID:
19969103
15.

Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis.

Abbott KL, Lim JM, Wells L, Benigno BB, McDonald JF, Pierce M.

Proteomics. 2010 Feb;10(3):470-81. doi: 10.1002/pmic.200900537.

16.

Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines.

Guan W, Zhou M, Hampton CY, Benigno BB, Walker LD, Gray A, McDonald JF, Fernández FM.

BMC Bioinformatics. 2009 Aug 22;10:259. doi: 10.1186/1471-2105-10-259.

17.

Ephraim McDowell and Jane Todd Crawford: the bicentennial of a surgical masterpiece.

Benigno BB.

Obstet Gynecol. 2009 May;113(5):1141-4. doi: 10.1097/AOG.0b013e31819daf78. No abstract available.

PMID:
19384132
18.

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells.

Scharer CD, Laycock N, Osunkoya AO, Logani S, McDonald JF, Benigno BB, Moreno CS.

J Transl Med. 2008 Dec 11;6:79. doi: 10.1186/1479-5876-6-79.

19.

Epigenetic changes within the promoter region of the HLA-G gene in ovarian tumors.

Menendez L, Walker LD, Matyunina LV, Totten KA, Benigno BB, McDonald JF.

Mol Cancer. 2008 May 22;7:43. doi: 10.1186/1476-4598-7-43.

20.

Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas.

Moreno CS, Matyunina L, Dickerson EB, Schubert N, Bowen NJ, Logani S, Benigno BB, McDonald JF.

PLoS One. 2007 May 16;2(5):e441.

Supplemental Content

Loading ...
Support Center